Why Anti-Obesity Drugs Could Become Pharma’s Largest Revenue Segment by 2035
The anti-obesity drugs market is poised for explosive growth, expanding from around $5B in 2025 to potentially over $100B by 2035. Driven by rising global obesity rates, low treatment penetration, and breakthroughs in GLP-1 therapies, this segment is evolving into a high-demand, chronic treatment market. Strong innovation pipelines, increasing adoption, and broad industry impact position anti-obesity drugs as a future dominant revenue driver in the pharmaceutical sector.
Read More